Introduction: Gastric cancer is the fifth most common cancer and third leading cause of cancer-related death worldwide. There are three main ways to treat gastric cancer: surgical resection, radiation therapy, and drug therapy. Furthermore, combinations of two to three regimens can improve survival. However, the survival outcomes of chemotherapy in advanced gastric cancer patients are still unsatisfactory. Unfortunately, no widely useful biomarkers have been verified to predict the efficacy of chemotherapy for locally advanced gastric cancer. Methods: An MTT assay was used to determine the cell viability after cisplatin or oxaliplatin treatment. Western blotting and immunohistochemistry were utilized to examine the secreted frizzled-related protein 4 (sFRP4) level and associated signaling pathways. Immunofluorescence staining was utilized to analyze the location of β-catenin. Colony formation and Transwell assays were used to analyze the functions related with cisplatin, oxaliplatin, and sFRP4. Results: We have found that gastric cancer patients treated with combinations of 5-fluorouracil (5-FU) and cisplatin regimens have better survival rates than those treated with 5-FU-based chemotherapy alone. sFRP4 was selected as a potential target from stringent analysis and intersection of 5-FU and cisplatin resistance-related gene sets. sFRP4 was shown to be overexpressed in clinical gastric tumor tissues and positively correlated with a worse survival rate. In addition, sFRP4 and β-catenin were upregulated in cisplatin- and oxaliplatin-resistant gastric cancer cells compared to parental cells. Immunofluorescence staining and nuclear fractionation showed that β-catenin was translocated from the cytosol into the nucleus. Moreover, sFRP4 was detected in the conditioned medium of these resistant cells, which indicates that sFRP4 might have an extracellular role in chemotherapy resistance. Increased migration capacity and dysregulation of epithelial-mesenchymal transition-related markers, which might result from the dysregulation of sFRP4, were observed in cisplatin- and oxaliplatin-resistant gastric cancer cells. Discussion/Conclusion: In summary, sFRP4 might play a critical role in resistance to cisplatin and oxaliplatin, cell metastasis, and poor prognosis in gastric cancer via the Wnt-β-catenin pathway. Investigations of the molecular mechanism underlying sFRP4-modulated cancer progression and chemotherapeutic outcomes can provide additional therapeutic strategies for gastric cancer.

1.
Sung
H
,
Ferlay
J
,
Siegel
RL
,
Laversanne
M
,
Soerjomataram
I
,
Jemal
A
, et al
.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
.
CA Cancer J Clin
.
2021
;
71
(
3
):
209
49
. .
2.
Cheong
JH
,
Yang
HK
,
Kim
H
,
Kim
WH
,
Kim
YW
,
Kook
MC
, et al
.
Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis
.
Lancet Oncol
.
2018
;
19
(
5
):
629
38
. .
3.
Wang
K
,
Yuen
ST
,
Xu
J
,
Lee
SP
,
Yan
HH
,
Shi
ST
, et al
.
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
.
Nat Genet
.
2014
;
46
(
6
):
573
82
. .
4.
Snow
GE
,
Kasper
AC
,
Busch
AM
,
Schwarz
E
,
Ewings
KE
,
Bee
T
, et al
.
Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting
.
BMC Cancer
.
2009
;
9
:
383
. .
5.
Koushyar
S
,
Powell
AG
,
Vincan
E
,
Phesse
TJ
.
Targeting Wnt signaling for the treatment of gastric cancer
.
Int J Mol Sci
.
2020
;
21
(
11
):
3927
.
6.
Surana
R
,
Sikka
S
,
Cai
W
,
Shin
EM
,
Warrier
SR
,
Tan
HJ
, et al
.
Secreted frizzled related proteins: implications in cancers
.
Biochim Biophys Acta
.
2014
;
1845
(
1
):
53
65
. .
7.
Zhou
Z
,
Wang
J
,
Han
X
,
Zhou
J
,
Linder
S
.
Up-regulation of human secreted frizzled homolog in apoptosis and its down-regulation in breast tumors
.
Int J Cancer
.
1998
;
78
(
1
):
95
9
. .
8.
Kawano
Y
,
Kypta
R
.
Secreted antagonists of the Wnt signalling pathway
.
J Cell Sci
.
2003
;
116
(
Pt 13
):
2627
34
. .
9.
He
TC
,
Sparks
AB
,
Rago
C
,
Hermeking
H
,
Zawel
L
,
da Costa
LT
, et al
.
Identification of c-MYC as a target of the APC pathway
.
Science
.
1998
;
281
(
5382
):
1509
12
. .
10.
Tetsu
O
,
McCormick
F
.
Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells
.
Nature
.
1999
;
398
(
6726
):
422
6
. .
11.
Zhang
T
,
Otevrel
T
,
Gao
Z
,
Gao
Z
,
Ehrlich
SM
,
Fields
JZ
, et al
.
Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer
.
Cancer Res
.
2001
;
61
(
24
):
8664
7
.
12.
Nusse
R
,
Varmus
HE
.
Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome
.
Cell
.
1982
;
31
(
1
):
99
109
. .
13.
Bovolenta
P
,
Esteve
P
,
Ruiz
JM
,
Cisneros
E
,
Lopez-Rios
J
.
Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease
.
J Cell Sci
.
2008
;
121
(
Pt 6
):
737
46
. .
14.
Frank
B
,
Hoffmeister
M
,
Klopp
N
,
Illig
T
,
Chang-Claude
J
,
Brenner
H
.
Single nucleotide polymorphisms in Wnt signaling and cell death pathway genes and susceptibility to colorectal cancer
.
Carcinogenesis
.
2010
;
31
(
8
):
1381
6
. .
15.
Froeling
FE
,
Feig
C
,
Chelala
C
,
Dobson
R
,
Mein
CE
,
Tuveson
DA
, et al
.
Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-beta-catenin signaling to slow tumor progression
.
Gastroenterology
.
2011
;
141
(
4
):
1486
97
. .
16.
Longman
D
,
Arfuso
F
,
Viola
HM
,
Hool
LC
,
Dharmarajan
AM
.
The role of the cysteine-rich domain and netrin-like domain of secreted frizzled-related protein 4 in angiogenesis inhibition in vitro
.
Oncol Res
.
2012
;
20
(
1
):
1
6
. .
17.
Wu
Y
,
Liu
C
,
Yu
S
,
Gao
H
,
Li
Z
,
Li
C
, et al
.
Assessment of sFRP4 as a bio-marker for predicting aggressiveness and recurrence of growth hormone-secreting pituitary adenomas
.
Oncol Rep
.
2016
;
35
(
5
):
2991
9
. .
18.
Sandsmark
E
,
Andersen
MK
,
Bofin
AM
,
Bertilsson
H
,
Drabløs
F
,
Bathen
TF
, et al
.
SFRP4 gene expression is increased in aggressive prostate cancer
.
Sci Rep
.
2017
;
7
(
1
):
14276
. .
19.
Yu
P
,
He
W
,
Zhang
Y
,
Hu
C
,
Wu
Y
,
Wang
Y
, et al
.
SFRP4 is a potential biomarker for the prognosis and immunotherapy for gastric cancer
.
J Oncol
.
2022
;
2022
:
8829649
. .
20.
Busuttil
RA
,
George
J
,
House
CM
,
Lade
S
,
Mitchell
C
,
Di Costanzo
NS
, et al
.
SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence
.
Gastric Cancer
.
2021
;
24
(
3
):
589
601
. .
21.
Kim
YM
,
Kwon
IG
,
Choi
SH
,
Noh
SH
,
Chun
J
,
Youn
YH
, et al
.
SFRP4 and CDX1 are predictive genes for extragastric recurrence of early gastric cancer after curative resection
.
J Clin Med
.
2022
;
11
(
11
):
3072
. .
22.
Li
H
,
Zhao
J
,
Sun
J
,
Tian
C
,
Jiang
Q
,
Ding
C
, et al
.
Demethylation of the SFRP4 promoter drives gastric cancer progression via the Wnt pathway
.
Mol Cancer Res
.
2021
;
19
(
9
):
1454
64
. .
23.
Liu
D
,
Sun
C
,
Kim
N
,
Bhan
C
,
Tuason
JPW
,
Chen
Y
, et al
.
Comprehensive analysis of SFRP family members prognostic value and immune infiltration in gastric cancer
.
Life
.
2021
;
11
(
6
):
522
. .
24.
Nfonsam
LE
,
Jandova
J
,
Jecius
HC
,
Omesiete
PN
,
Nfonsam
VN
.
SFRP4 expression correlates with epithelial mesenchymal transition-linked genes and poor overall survival in colon cancer patients
.
World J Gastrointest Oncol
.
2019
;
11
(
8
):
589
98
. .
25.
Warrier
S
,
Bhuvanalakshmi
G
,
Arfuso
F
,
Rajan
G
,
Millward
M
,
Dharmarajan
A
.
Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition
.
Cancer Gene Ther
.
2014
;
21
(
9
):
381
8
. .
26.
Deshmukh
A
,
Kumar
S
,
Arfuso
F
,
Newsholme
P
,
Dharmarajan
A
.
Secreted Frizzled-related protein 4 (sFRP4) chemo-sensitizes cancer stem cells derived from human breast, prostate, and ovary tumor cell lines
.
Sci Rep
.
2017
;
7
(
1
):
2256
. .
27.
Odero-Marah
V
,
Hawsawi
O
,
Henderson
V
,
Sweeney
J
.
Epithelial-Mesenchymal Transition (EMT) and prostate cancer
.
Adv Exp Med Biol
.
2018
;
1095
:
101
10
. .
28.
Sweeney
JD
,
Debeljak
M
,
Riel
S
,
Millena
AC
,
Eshleman
JR
,
Paller
CJ
, et al
.
Val16A SOD2 polymorphism promotes epithelial-mesenchymal transition antagonized by muscadine grape skin extract in prostate cancer cells
.
Antioxidants
.
2021
;
10
(
2
):
213
. .
29.
Nieto
MA
.
The ins and outs of the epithelial to mesenchymal transition in health and disease
.
Annu Rev Cell Dev Biol
.
2011
;
27
:
347
76
. .
30.
Maganga
R
,
Giles
N
,
Adcroft
K
,
Unni
A
,
Keeney
D
,
Wood
F
, et al
.
Secreted Frizzled related protein-4 (sFRP4) promotes epidermal differentiation and apoptosis
.
Biochem Biophys Res Commun
.
2008
;
377
(
2
):
606
11
. .
31.
Lee
AY
,
He
B
,
You
L
,
Dadfarmay
S
,
Xu
Z
,
Mazieres
J
, et al
.
Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma
.
Oncogene
.
2004
;
23
(
39
):
6672
6
. .
32.
Wang
KS
,
Hu
ZL
,
Li
JH
,
Xiao
DS
,
Wen
JF
.
Enhancement of metastatic and invasive capacity of gastric cancer cells by transforming growth factor-beta1
.
Acta Biochim Biophys Sin
.
2006
;
38
(
3
):
179
86
. .
33.
Polakis
P
.
Wnt signaling and cancer
.
Genes Dev
.
2000
;
14
(
15
):
1837
51
. .
34.
Lustig
B
,
Behrens
J
.
The Wnt signaling pathway and its role in tumor development
.
J Cancer Res Clin Oncol
.
2003
;
129
(
4
):
199
221
. .
35.
Chung
MT
,
Lai
HC
,
Sytwu
HK
,
Yan
MD
,
Shih
YL
,
Chang
CC
, et al
.
SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway
.
Gynecol Oncol
.
2009
;
112
(
3
):
646
53
. .
36.
Nakajima
T
,
Kinoshita
T
,
Nashimoto
A
,
Sairenji
M
,
Yamaguchi
T
,
Sakamoto
J
, et al
.
Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer
.
Br J Surg
.
2007
;
94
(
12
):
1468
76
. .
37.
Sasako
M
,
Sakuramoto
S
,
Katai
H
,
Kinoshita
T
,
Furukawa
H
,
Yamaguchi
T
, et al
.
Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer
.
J Clin Oncol
.
2011
;
29
(
33
):
4387
93
. .
38.
Noh
SH
,
Park
SR
,
Yang
HK
,
Chung
HC
,
Chung
IJ
,
Kim
SW
, et al
.
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
.
Lancet Oncol
.
2014
;
15
(
12
):
1389
96
. .
39.
Sexton
RE
,
Al Hallak
MN
,
Diab
M
,
Azmi
AS
.
Gastric cancer: a comprehensive review of current and future treatment strategies
.
Cancer Metastasis Rev
.
2020
;
39
(
4
):
1179
203
. .
40.
Lyman
GH
.
Impact of chemotherapy dose intensity on cancer patient outcomes
.
J Natl Compr Canc Netw
.
2009
;
7
(
1
):
99
108
. .
41.
Petrelli
F
,
Berenato
R
,
Turati
L
,
Mennitto
A
,
Steccanella
F
,
Caporale
M
, et al
.
Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis
.
J Gastrointest Oncol
.
2017
;
8
(
1
):
148
63
. .
42.
Sorrentino
L
,
De Ruvo
N
,
Serra
F
,
Salati
M
,
Ricciardolo
AA
,
Bonetti
LR
, et al
.
Role of poorly differentiated cluster in gastric cancer: is it a new prognosis factor
.
Scand J Gastroenterol
.
2022
;
57
(
1
):
44
9
. .
43.
Kemi
N
,
Eskuri
M
,
Herva
A
,
Leppänen
J
,
Huhta
H
,
Helminen
O
, et al
.
Tumour-stroma ratio and prognosis in gastric adenocarcinoma
.
Br J Cancer
.
2018
;
119
(
4
):
435
9
. .
44.
Park
WJ
,
Kim
MJ
.
A new wave of targeting “undruggable” Wnt signaling for cancer therapy: challenges and opportunities
.
Cells
.
2023
;
12
(
8
):
1110
. .
45.
Kim
MJ
,
Huang
Y
,
Park
JI
.
Targeting Wnt signaling for gastrointestinal cancer therapy: present and evolving views
.
Cancers
.
2020
;
12
(
12
):
3638
. .
46.
Sundaram
SM
,
Varier
L
,
Fathima
KZ
,
Dharmarajan
A
,
Warrier
S
.
Short peptide domains of the Wnt inhibitor sFRP4 target ovarian cancer stem cells by neutralizing the Wnt beta-catenin pathway, disrupting the interaction between beta-catenin and CD24 and suppressing autophagy
.
Life Sci
.
2023
;
316
:
121384
. .
47.
He
X
,
Semenov
M
,
Tamai
K
,
Zeng
X
.
LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way
.
Development
.
2004
;
131
(
8
):
1663
77
. .
48.
Ford
CE
,
Jary
E
,
Ma
SS
,
Nixdorf
S
,
Heinzelmann-Schwarz
VA
,
Ward
RL
.
The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells
.
PLoS One
.
2013
;
8
(
1
):
e54362
. .
49.
Lin
K
,
Wang
S
,
Julius
MA
,
Kitajewski
J
,
Moos
M
Jr
,
Luyten
FP
.
The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for modulation of Wnt signaling
.
Proc Natl Acad Sci U S A
.
1997
;
94
(
21
):
11196
200
. .
50.
Lopez-Rios
J
,
Esteve
P
,
Ruiz
JM
,
Bovolenta
P
.
The Netrin-related domain of Sfrp1 interacts with Wnt ligands and antagonizes their activity in the anterior neural plate
.
Neural Dev
.
2008
;
3
:
19
. .
51.
Horvath
LG
,
Henshall
SM
,
Kench
JG
,
Saunders
DN
,
Lee
CS
,
Golovsky
D
, et al
.
Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro
.
Clin Cancer Res
.
2004
;
10
(
2
):
615
25
. .
52.
Horvath
LG
,
Lelliott
JE
,
Kench
JG
,
Lee
CS
,
Williams
ED
,
Saunders
DN
, et al
.
Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer
.
Prostate
.
2007
;
67
(
10
):
1081
90
. .
53.
Mortensen
MM
,
Høyer
S
,
Lynnerup
AS
,
Ørntoft
TF
,
Sørensen
KD
,
Borre
M
, et al
.
Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy
.
Sci Rep
.
2015
;
5
:
16018
. .
You do not currently have access to this content.